The spread of drug-resistant bacteria is a global health concern and could once again become a leading cause of mortality. The World Health Organization has flagged carbapenem-resistant Acinetobacter baumannii (CRAB), which has a mortality rate of 25%-60%, as a top priority pathogen requiring innovative therapies for its management. Researchers from the HUN-REN Biological Research Centre in Hungary have published a paper in Cell in which they describe designing and developing phage cocktails that target the most prevalent CRAB strains within specific geographic regions by using phylogeographic analysis and mapping the pathogen’s genetic diversity.
Novartis AG is enlisting the help of Generate:Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick the targets, although the targets Generate has been working on are off limits. Generate will be responsible for creating the lead candidate, at which point Novartis will take over development.
Cancer Research Technology Ltd. and My-T Bio Ltd. have jointly developed biarylamide derivatives acting as membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) inhibitors with potential for the treatment of cancer.
Work at Axcynsis Therapeutics Pte. Ltd. has led to the creation of antibody-drug conjugates (ADCs) comprising antibodies covalently linked to ecteinascidin and lurbinectedin derivatives through a linker; they are reported to be useful for the treatment of cancer.
Vividion Therapeutics Inc. has patented 2-azaspiro[3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based on a previously described PD-L1 inhibitor, and systematic screening of ligands and linkers, combined with structure-activity relationship analysis of the degraders, led to the identification of compounds [I] and [II] as the most active candidates.
Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
RSS
